Last reviewed · How we verify
NCT05835115
Development and Validation of a Deep Learning-based Myopia and Myopic Maculopathy Detection and Prediction System
trial testing A deep learning-based myopia and myopic maculopathy detection and prediction system in Myopia in 30,526 participants. Completed in 1 April 2023.
1 April 2023
Quick facts
| Lead sponsor | Shanghai Eye Disease Prevention and Treatment Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30,526 |
| Start date | 1 April 2022 |
| Primary completion | 1 April 2023 |
| Estimated completion | 1 April 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- A deep learning-based myopia and myopic maculopathy detection and prediction system
Conditions studied
- Myopia — all drugs for Myopia →
- Myopic Macular Degeneration — all drugs for Myopic Macular Degeneration →
Sponsor
Shanghai Eye Disease Prevention and Treatment Center — full company profile →
Who can join
Adults 4 to 18, any sex, with Myopia or Myopic Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Myopia has become a global public health issue. Myopia affects the psychological health of children and adolescents and poses a financial burden. Therefore, early detection and prediction of children at a high risk of myopia development and progression are critical for precise and effective interventions. In this study, we developed a deep learning system DeepMyopia, based on fundus images with the following objectives: 1) to predict myopia onset and progression; 2) To detect myopic macular degeneration for AI-assisted diagnosis; 3) To predict the development of myopic macular degeneration; 4) evaluate its cost-effectiveness.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A deep learning system for myopia onset prediction and intervention effectiveness evaluation in children.
Qi Z, Li T, Chen J, Yam JC, et al · · 2024 · cited 17× · PMID 39112566 · DOI 10.1038/s41746-024-01204-7
Verify or expand the search:
- PubMed search for NCT05835115
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myopia
Currently open trials in the same condition.
- NCT07284966 — Comfort and Vision With TOTAL30 Multifocal Lenses · recruiting
- NCT07078799 — Wavefront-guided LASIK Surgery Compared to Ray Tracing-Guided LASIK Surgery · NA · recruiting
- NCT07585877 — Effect of Branched-Chain Amino Acid Supplementation on Myopia Progression · NA · active not recruiting
- NCT07354945 — An Evaluation of Myopia Control Lenses on Wearing Experience in Myopic Children · NA · recruiting
- NCT07229365 — Children's Viewing Behavior · NA · recruiting
Other Shanghai Eye Disease Prevention and Treatment Center trials
Trials by the same sponsor.
- NCT07535658 — Efficacy of Multi-Type Photolithography Flat Microstructure Lenses for Childhood Myopia Control · NA · not yet recruiting
- NCT07514039 — Photolithography Microstructure Myopia Management Lenses in Preventing and Controlling Myopia in Children and Adolescent · NA · enrolling by invitation
- NCT07312214 — LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia · NA · recruiting
- NCT07284147 — 3D Designed Defocus Lenses on Myopia Control in Children and Adolescents · NA · enrolling by invitation
- NCT07120737 — Efficacy and Safety of Spectacle Lenses With H.A.L.T. MAX Technology on High Myopia Control in Children and Adolescents · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05835115 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Eye Disease Prevention and Treatment Center
- Last refreshed: 28 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05835115.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing